Low risk of malformation in children fathered by men treated for testicular germ-cell cancer

Jun 17, 2019

In June Lunds University announced the results of this nation-wide register study, which was published in PLOS Medicine and has been co-funded by ReproUnion. 

According to PLOS Medicine the study investigates whether receiving treatment for testicular cancer, being the most common cancer among young men (in child-having ages), leads to a higher risk of fathering a child with a birth defect. 

Chemotherapy and radiotherapy have both been shown to cause mutations and genetic damage in animal studies, leading to fears that men being treated with these therapies might be more prone to have children with genetic diseases and birth defects.

By accessing data from Swedish national registries, scientists gathered data on more than 2 million newborns and their fathers. Among them, 2,380 fathers had testicular cancer and they had, in total, 4,207 children.

“When comparing the children conceived after the father received cancer treatment to the children born before treatment, we could not find any evidence showing that chemotherapy or radiotherapy leads to an increased risk of birth defects”, said Yahia Al-Jebari, Post Doc, Reproductive Medicine at Lunds University. He carried out the research with amongst others Aleksander Giwercman, Professor in Reproductive Medicine at Lund’s University and chief physicians at Skåne’s University Hospital.

You can find the Publication via this link to PLOS Medicine, as well as the first news release from Lunds University (in Swedish) 


Engage with ReproUnion at Folkemødet

Come join us to learn more about how ReproUnion aim at patient centered care for infertile patients through the establishment of an Innovation platform and projects run in close collaboration between academia, public hospitals, industry and incubators. ReproUnion...

read more

It’s a couple issue!

At the Women's health network meeting: "Driving innovation and empowerment to improve women´s health", arranged by Hologic, Inc. and Medicon Valley Alliance, Lærke Priskorn, Researcher at Department of Growth and Reproduction, Rigshospitalet was one of four Nordic...

read more

EU-money to ignite startups within fertility

10. January 2024 by Keld Broksø The fertility research collaboration ReproUnion has received new EU funding. Now, the Øresund collaboration, whose total budget amounts to more than 300 million SEK, will include and initiate innovation companies. Startups and new...

read more